ANALYST BRIEFING · Q4 2026
Generative AI in pharma R&D: where the value is real.
We mapped 23 use cases across 40 sponsors. Four are ready to fund now.
NORTHWIND RESEARCH04
START HERE
Regulatory writing
Literature review
Protocol drafting
Safety case triage
Molecule screening
Trial site selection
Lab notebook search
Recruitment ads
LOWREADINESS →
VALUE →
OUR POINT OF VIEW
Most GenAI in R&D is stuck in pilots because it’s aimed at the wrong step.
01
Discovery gets the headlines
but trial operations hold the money.
02
The bottleneck is documents
protocols, CSRs and submissions, not molecules.
03
Value comes from agents
that sit inside existing clinical systems.
NORTHWIND RESEARCH · ANALYST BRIEFING02
EXHIBIT 2 · WHERE THE VALUE IS
Trial operations hold more value ready now than discovery and pre-clinical combined.
Annual value at stake, $B, top-40 sponsorsReady now2028 and later
Discovery61420
Pre-clinical91120
Clinical trials311243
Regulatory18725
SOURCE: NORTHWIND RESEARCH, 23 USE CASES ACROSS 40 SPONSORS03
OUR PRACTICE IN NUMBERS
A life sciences practice built for regulated work.
40
pharma and biotech sponsors as clients
23
GenAI use cases mapped and scored
650
life sciences specialists, GxP trained
9
GenAI systems in validated production
NORTHWIND RESEARCH · ANALYST BRIEFING04
CLIENT EVIDENCE
Three results clients will speak to.
TOP-10 PHARMA
6 wks → 9 days
Protocol first drafts, reviewed by medical writers.
MID-SIZE BIOTECH
40% faster
Clinical study reports across three phase II trials.
GLOBAL CRO
3× more sites
Screened per week with an agent on feasibility data.
NORTHWIND RESEARCH · ANALYST BRIEFING05
EXHIBIT 5 · WHERE WE’RE INVESTING
Four bets for the next twelve months, sequenced by readiness.
Q1 2027Q2Q3Q4
Agentic trial operationsTwo sponsors live
Submission copiloteCTD with full traceability
Real-world evidence platformWith two top-10 sponsors
Validated GenAI factoryGxP pipeline for every new use case
NORTHWIND RESEARCH · INVESTMENT ROADMAP06
FOR YOUR NOTES
What we’d like you to take away.
01Trial operations, not discovery, is where GenAI pays back first.
02Northwind has nine validated GenAI systems in production today.
03Clients in our evidence are available for reference calls.
Analyst relations · ar@northwind.com
NORTHWIND RESEARCH · ANALYST BRIEFING07
